Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBetsyon Sep 21, 2024 9:31am
245 Views
Post# 36234525

RE:PROXY VOTE AGAINST

RE:PROXY VOTE AGAINSTGood luck goldtech a few Boston group shareholders will easily push this through they control this company. I don't understand the Sphera comments ? Total institutional shares at the time of last financing was 10.9%, will see 45 days after sep 30 updated numbers but i doubt much of a change.

If Promis goes into the clinic testing alzheimers patients it will take many years to prove the science not just promising or encouraging interim results. 

Alzheon the alzheimers pill looks strong and encouraging and may headed for approvals, will see this fall. This could be a game changer.

Roche also this fall Prrasinezmab with Parkinsons Prothena 

Prothena this fall PRX012 update, they have pushed off topline results 

<< Previous
Bullboard Posts
Next >>